Register Login

BRIDGEBIO PHARMA, INC. (BBIO)

SymbolBBIO
NameBRIDGEBIO PHARMA, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address421 KIPLING STREET, PALO ALTO, California, 94301, United States
Telephone+1 650 391-9740
Fax—
Email—
Websitehttps://www.bridgebio.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK—
Description

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

Additional info from NASDAQ:
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

2026-04-24 17:27

New Form ARS - BridgeBio Pharma, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001140361-26-016725 <b>Size:</b> 2 MB

Read more
2026-04-24 17:26

New Form DEFA14A - BridgeBio Pharma, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001140361-26-016724 <b>Size:</b> 3 MB

Read more
2026-04-24 17:25

New Form DEF 14A - BridgeBio Pharma, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001140361-26-016723 <b>Size:</b> 8 MB

Read more
2026-04-22 11:30

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-04-16 17:36

New Form SCHEDULE 13G/A - BridgeBio Pharma, Inc. <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001470831-26-000373 <b>Size:</b> 8 KB

Read more
2026-04-13 22:06

Director Kumar Neil 🔴 sold 80.0K shares of BridgeBio Pharma, Inc. (BBIO) at $75.55 ($6.0M) Transaction Date: Apr 09, 2026 | Filing ID: 000361

Read more
2026-04-09 20:23

📋 KUMAR HALDEA REVOCABLE TRUST U/A DTD 12/19/2018 (Director) plans to sell 120K shares of BRIDGEBIO PHARMA INC (at $74.14 each, total $8.9M) Filed: Apr 09, 2026 | ID: 003358

Read more
2026-04-02 19:40

New Form SCHEDULE 13D/A - BridgeBio Pharma, Inc. <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0000905148-26-001499 <b>Size:</b> 38 KB

Read more
2026-03-30 21:30

(90% Positive) BRIDGEBIO PHARMA, INC. (BBIO) Provides Update on individuals living for genetic conditions

Read more
2026-03-30 19:30

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06917079 BBO-11818 in Adult Subjects With KRAS Mutant Cancer Phase1 Non-Small Cell Lung Cancer Recruiting 2025-03-31 2029-09-01 ClinicalTrials.gov
NCT05735015 PTH-independent Effects of Encaleret Phase2 Post-Surgical Hypoparathyroidism Completed 2023-09-01 2025-08-12 ClinicalTrials.gov
NCT05480865 SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced … Phase1 Solid Tumor, Adult Terminated 2022-07-06 2024-08-22 ClinicalTrials.gov
NCT04528836 First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced So… Phase1 Tumor, Solid Terminated 2020-11-12 2024-07-30 ClinicalTrials.gov
NCT04265651 Study of Infigratinib in Children With Achondroplasia Phase2 Achondroplasia Completed 2020-03-10 2024-10-21 ClinicalTrials.gov
Total clinical trials: 5
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Encaleret Other Phase PHASE2 Autosomal Dominant Hypocalcemia Type 1 (ADH1) RECRUITING NCT07080385
Encaleret Other Phase PHASE2 Autosomal Dominant Hypocalcemia Type 1 (ADH1) RECRUITING NCT07080385
Encaleret Other Phase PHASE2 Autosomal Dominant Hypocalcemia Type 1 (ADH1) RECRUITING NCT07080385
Encaleret Other Phase PHASE2 Autosomal Dominant Hypocalcemia Type 1 (ADH1) RECRUITING NCT07080385
Encaleret Other Phase PHASE2 Autosomal Dominant Hypocalcemia Type 1 (ADH1) RECRUITING NCT07080385
Encaleret Other Phase PHASE2 Autosomal Dominant Hypocalcemia Type 1 (ADH1) RECRUITING NCT07080385
Encaleret Other Phase PHASE2 Autosomal Dominant Hypocalcemia Type 1 (ADH1) RECRUITING NCT07080385
Encaleret Other Phase PHASE2 Autosomal Dominant Hypocalcemia Type 1 (ADH1) RECRUITING NCT07080385
infigratinib 0.25 mg/kg/day DRUG Phase PHASE2 Hypochondroplasia ENROLLING_BY_INVITATION NCT06873035
infigratinib 0.128 mg/kg/day DRUG Phase PHASE2 Hypochondroplasia ENROLLING_BY_INVITATION NCT06873035
Cardiac amyloidosis deep learning model DEVICE Approved Cardiac Amyloidosis COMPLETED NCT06469372
PTR-01 DRUG Phase PHASE2 Recessive Dystrophic Epidermolysis Bullosa COMPLETED NCT05143190
Iopamidol DRUG Phase PHASE1 Breast Cancer TERMINATED NCT04504331
Omnipaque 350 DRUG Phase PHASE1 Breast Cancer TERMINATED NCT04504331
Tamoxifen DRUG Phase PHASE1 Breast Cancer TERMINATED NCT04504331
BGJ398 (infigratinib) DRUG Phase PHASE2 Advanced Cholangiocarcinoma TERMINATED NCT02150967
BBP-671 DRUG Phase PHASE1 Healthy Volunteers TERMINATED NCT04836494
Placebo DRUG Phase PHASE1 Healthy Volunteers TERMINATED NCT04836494
Cisplatin DRUG Phase PHASE3 Advanced Cholangiocarcinoma TERMINATED NCT03773302
BGJ398 DRUG Phase PHASE3 Advanced Cholangiocarcinoma TERMINATED NCT03773302
sotorasib DRUG Phase PHASE1 Solid Tumor, Adult TERMINATED NCT05480865
BBP-398 DRUG Phase PHASE1 Solid Tumor, Adult TERMINATED NCT05480865
BBP-398 (Formerly known as IACS-15509) DRUG Phase PHASE1 Tumor, Solid TERMINATED NCT04528836
Placebo Comparator 0.25 mg/kg/day DRUG Phase PHASE3 Achondroplasia ACTIVE_NOT_RECRUITING NCT06164951
Infigratinib 0.25 mg/kg/day DRUG Phase PHASE3 Achondroplasia ACTIVE_NOT_RECRUITING NCT06164951
Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration DRUG Phase PHASE2 Achondroplasia NOT_YET_RECRUITING NCT07169279
Infigratinib is provided as sprinkle capsules for daily oral administration DRUG Phase PHASE2 Achondroplasia NOT_YET_RECRUITING NCT07169279
Infigratinib is provided as a single dose of minitablets for oral administration DRUG Phase PHASE2 Achondroplasia NOT_YET_RECRUITING NCT07169279
Infigratinib 0.25 mg/kg DRUG Phase PHASE2 Achondroplasia COMPLETED NCT04265651
Infigratinib 0.128 mg/kg DRUG Phase PHASE2 Achondroplasia COMPLETED NCT04265651
Infigratinib 0.064 mg/kg DRUG Phase PHASE2 Achondroplasia COMPLETED NCT04265651
Infigratinib 0.032 mg/kg DRUG Phase PHASE2 Achondroplasia COMPLETED NCT04265651
Infigratinib 0.016 mg/kg DRUG Phase PHASE2 Achondroplasia COMPLETED NCT04265651
Infigratinib DRUG Phase PHASE1 Bladder Transitional Cell Carcinoma WITHDRAWN NCT04972253
ALXN2060 DRUG Phase PHASE3 Symptomatic Transthyretin Amyloid Cardiomyopathy COMPLETED NCT04622046
Encaleret DRUG Phase PHASE2 Autosomal Dominant Hypocalcemia (ADH) COMPLETED NCT04581629
encaleret DRUG Phase PHASE2 Post-Surgical Hypoparathyroidism COMPLETED NCT05735015
Nab-paclitaxel DRUG Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT06917079
Gemcitabine DRUG Phase PHASE3 Advanced Cholangiocarcinoma TERMINATED NCT03773302
NALIRIFOX DRUG Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT06917079
Cetuximab DRUG Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT06917079
Pemetrexed DRUG Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT06917079
Platinum chemotherapy (cisplatin or carboplatin) DRUG Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT06917079
BBO-11818 DRUG Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT06917079
Pembrolizumab DRUG Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT06917079
BBO-8520 DRUG Phase PHASE1 Non-small Cell Lung Cancer RECRUITING NCT06343402
Bevacizumab DRUG Phase PHASE1 Solid Tumor, Adult RECRUITING NCT06625775
FOLFOX DRUG Phase PHASE1 Non-Small Cell Lung Cancer RECRUITING NCT06917079
Ribociclib DRUG Phase PHASE1 Solid Tumor, Adult RECRUITING NCT06625775
Fulvestrant DRUG Phase PHASE1 Solid Tumor, Adult RECRUITING NCT06625775
Trastuzumab DRUG Phase PHASE1 Solid Tumor, Adult RECRUITING NCT06625775
BBO-10203 DRUG Phase PHASE1 Non-small Cell Lung Cancer RECRUITING NCT06343402
Total products: 52